All studies
Cardiology · EHR · China
Chen 2026
Drug-induced QT prolongation
QBA performedITTSuperiorityAcademia4/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- 1:1 propensity-score matching
- Analysis method
- Matched linear regression
- Missing data
- Complete case
- DAG
- No
- QBA
- Yes
Data and sample
- Data type
- EHR
- Data sources
- 4
- Geography
- China
- Eligible sample
- 98860
- Treated
- 49430
- Control
- 49430
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Available on reasonable request subject to data-use approval
- Code availability
- Available on reasonable request
- Conflicts of interest
- Declared: None
- Funding
- Declared: None
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2026_Chen_QTc
- DOI
- 10.1007/s00228-026-04076-w
- Affiliations
- Shanghai Sixth People's Hospital and participating Chinese hospitals
- Sector
- Academia
- Target trials (study level)
- Zhu rosuvastatin-atorvastatin QTc trial